Roche launches cobas p 480 instrument for high-volume, automated preanalytic processing of primary vial molecular diagnostic

 Roche launches cobas p 480 instrument for high-volume, automated preanalytic
           processing of primary vial molecular diagnostic samples

  PR Newswire

  PLEASANTON, California, Dec. 2, 2013

-- New system reduces laboratory hands-on time by 50% for liquid based
cytology samples, eliminating manual preparation steps and improving workflow

PLEASANTON, California, Dec. 2,2013 /PRNewswire/ -- Roche (SIX: RO, ROG;
OTCQX: RHHBY) announced today the launch of the cobas p 480 preanalytics
instrument for automated uncapping and recapping of primary sample vials used
for liquid-based cytology (LBC) and molecular assays run on the cobas ® 4800
System. For assays such as the cobas ® HPV and cobas ® CT/NG 4800 Test, the
cobas p 480 instrument provides significant workflow and sample integrity
advantages. By addressing the need to automate sample preparation, the cobas
p 480 helps to eliminate manual steps that can lead to repetitive motion
injury, a significant area of concern for laboratory workers that handle a
large number of samples each day.

Findings from an independent consulting firm show that when the p480
instrument is part of the workflow process, overall hands-on time for
delivering test results from over 700 samples per day is reduced by up to
50%. Preprocessing steps-- including: vial cap removal, vortexing and barcode
quality checks-- are automated, reducing the risk of sample mix-up, cross
contamination or user error and ensuring the reliability of test results. The
instrument allows primary vials to be loaded directly onto the cobas® 4800
System without a need to aliquot into a secondary vial. New caps can be
automatically re-placed on the primary vial for storage and post processing.

"For the first time, laboratories now have an option to directly load LBC
primary vials for preanalytical and analytical processing through a
combination of cobas ® systems that support molecular testing," said Paul
Brown, Head of Roche Molecular Diagnostics. "We are proud to bring solutions
to our laboratory partners that not only improve the quality of their test
results but solutions that can improve the quality of life for their employees
as well."

About the cobas® 4800 System The cobas ® 4800 System offers true walk-away
automation of nucleic acid purification, PCR (polymerase chain reaction)
set-up and real-time PCR amplification and detection to help laboratories
achieve maximum efficiency. The system runs the cobas ® HPV Test, cobas ®
CT/NG Test (chlamydia/gonorrhea), cobas ® BRAF V600 Mutation Test and the
cobas ® EGFR Mutation Test, along with an expanding menu of other molecular
diagnostic tests.

About Roche Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals and
diagnostics. Roche is the world's largest biotech company, with truly
differentiated medicines in oncology, infectious diseases, inflammation,
metabolism and neuroscience. Roche is also the world leader in in vitro
diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes
management. Roche's personalized healthcare strategy aims at providing
medicines and diagnostic tools that enable tangible improvements in the
health, quality of life and survival of patients. In 2012 Roche had over
82,000 employees worldwide and invested over 8 billion Swiss francs in R&D.
The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche is the majority
shareholder in Chugai Pharmaceutical, Japan. For more information, please
visit .

All trademarks used or mentioned are protected by law.

For media inquiries please contact: Bob PurcellVice President, Corporate

Press spacebar to pause and continue. Press esc to stop.